Which metabolic bone diseases are associated with brushite kidney stones?

Metabolic Bone Diseases Associated with Brushite Kidney Stones

Brushite kidney stones are primarily associated with distal renal tubular acidosis (dRTA) and absorptive hypercalciuria, with dRTA present in approximately 50% of brushite stone formers and absorptive hypercalciuria in 32-63% of cases. 1, 2

Primary Metabolic Bone Disease Associations

Distal Renal Tubular Acidosis (dRTA)

• dRTA is the most significant metabolic bone disease linked to brushite stones, occurring in 32-50% of brushite stone formers 1, 2
• This represents a dramatically higher prevalence compared to only 3% in calcium oxalate stone formers 2
• The failure of urine acidification in dRTA leads to persistently elevated urinary pH (mean 6.15), creating optimal conditions for brushite precipitation 2
• dRTA causes chronic metabolic acidosis, which directly contributes to bone demineralization and osteomalacia 3

Secondary Hyperparathyroidism and Hyperparathyroid Bone Disease

• Brushite stone formers with chronic kidney disease (CKD) frequently develop secondary hyperparathyroidism 3
• Elevated PTH levels drive high-turnover bone disease (osteitis fibrosa) characterized by increased bone resorption and abnormal bone formation 3
• The combination of hypercalciuria and elevated urinary pH in these patients creates a particularly high risk for brushite formation 1

Absorptive Hypercalciuria-Related Bone Loss

• Absorptive hypercalciuria type I is present in 32-63% of brushite stone formers, significantly higher than the 30% seen in calcium oxalate stone formers 1, 2
• Mean urinary calcium excretion in brushite patients (265 mg/day) is substantially elevated compared to other stone types 2
• Chronic hypercalciuria leads to negative calcium balance and progressive bone mineral density loss 4

Additional Metabolic Bone Considerations

Osteoporosis and Low Bone Mass

• Nephrolithiasis is now recognized as a systemic condition associated with increased risk of low bone mass 5
• The relationship between kidney stones and metabolic bone diseases creates significant economic and social burden due to high morbidity rates 4
• Dual X-ray absorptiometry (DXA) should be performed in brushite stone formers to assess bone mineral density 3, 4

Mixed Metabolic Abnormalities

• All brushite stone patients demonstrate at least one metabolic abnormality, with hypercalciuria (84.6%), elevated urine pH (61.5%), and hyperphosphaturia (43.1%) being most common 1
• Hyperabsorption of oxalate occurs in 41.2% of brushite stone formers, potentially contributing to mixed stone composition 1
• Approximately 61.5% of brushite stones are mixed with calcium oxalate and/or carbonate apatite 1

Clinical Implications and Monitoring

Diagnostic Approach

• Bone densitometry scanning combined with biochemistry is recommended for diagnosing metabolic bone disease in stone formers 3
• Serum intact PTH should be obtained when primary hyperparathyroidism is suspected (high or high-normal serum calcium) 3
• Metabolic testing should include 24-hour urine collections analyzing calcium, phosphate, pH, oxalate, citrate, and other parameters 3

Important Caveats

• The relative supersaturation of brushite does not differ significantly between patients with and without dRTA, suggesting other factors beyond pH contribute to stone formation 1
• Some evidence suggests iatrogenic transformation from calcium oxalate to brushite stone disease may occur following shock wave lithotripsy, potentially through nephron injury affecting urine acidification 6
• Brushite stones are particularly resistant to shock wave and ultrasonic lithotripsy, requiring more aggressive surgical intervention 6

Treatment Considerations

• Dietary intervention significantly reduces brushite supersaturation and should be integral to treatment, primarily through reducing urinary calcium, phosphate, and oxalate excretion 1
• Correction of metabolic acidosis with citrate and magnesium supplementation may prevent stone formation 3
• In CKD patients with elevated PTH, dietary phosphate restriction should be initiated, followed by active vitamin D sterols if ineffective 3